Methods Patients from two well-defined multiethnic and multi-center lupus cohorts, one from the US and the other from Latin America were included. SLE was defined in the US cohort using the 1982/1997 ACR criteria and as diagnosed by the physician for the Latin American cohort although more than 95% of these patients also achieved the 1982/1997 ACR criteria. For these analyses the 1982/1997 ACR criteria were used as the gold standard. Demographics and disease activity at baseline were compared in order to determine differences between those patients who achieved the EULAR/ACR criteria before, at the same time or after than 1982/1997 ACR criteria.

Results Five-hundred and fifty-eight patients out of 640 from the US cohort and 956 out of 1047 from the Latin American cohort achieved the EULAR/ACR criteria. The sensitivity of the EULAR/ACR criteria in the US cohort was 87.2% and in the Latin American cohort was 91.3%; in the US cohort, 41 (7.3%) achieved the EULAR/ACR criteria earlier, 344 (61.6%) at the same time and 173 (31.0%) later than the ACR criteria; for the Latin American cohort these numbers and percentages were 71 (7.4%), 556 (58.2%) and 329 (34.4%), respectively. Patients who achieved the EULAR/ACR criteria earlier were less likely to be Caucasian; disease activity (measured with the SLAM: systemic lupus activity measure for the US cohort, and with the SLEDAI: Systemic Lupus Erythematosus Disease Activity Index for the Latin American cohort) did not differ between the groups. These data are depicted in table 1.

Conclusions The sensitivity of the 2018 EULAR/ACR criteria against the 1982/1997 ACR criteria (gold standard) was high (87.2% for the USA and 91.3% for the Latin American cohort). While the large majority of patients were classified at the same time (58.2% to 61.6%) with both criteria, about one third were classified later and a small proportion (about 7%) were classified earlier with the 2018 EULAR/ACR criteria. Further examination of the 2018 EULAR/ACR criteria is warranted.

Funding Source(s): None

84

COMPARATIVE STUDY IN SLE PATIENTS WITH AND WITHOUT RENAL INVOLVEMENT BY LABEL FREE PROTEOMIC ANALYSIS OF URINE

¹Esther Ruiz*, ¹Natalia Rivera, ¹M Luz García, ¹Eva Galindez, ¹Ana Intxaurbe, ¹Juan Blanco, ¹Olaia Fernández, ¹Iñaki Torre, ¹Clara Pérez, ¹Itziar Calvo, ¹Oihane Ibargengoitia, ¹David Monterom, ¹Lucía Vega, ¹M Jesús Allande, ¹Helena Ugarte, ¹Unai Aresti, ²Mikel Azkargorta, ²Félix Elortza. ¹Osi Bilbao-Basurto; ²CIC bioGUNE, CIBERehd, ProteoRed-ISCIII

10.1136/lupus-2019-lsm.84

Background Lupus nephropathy (LN) is an important cause of morbidity and mortality in patients with Systemic Lupus Erythematosus (SLE). Considering that renal biopsy is a specialized technique and not risk free, a proteomics study is proposed to determine biomarkers that may help us to differentiate patients diagnosed with SLE with and without renal involvement.

Methods We selected 12 patients with SLE and renal involvement and 14 patients with SLE without renal involvement. There were no differences between groups according to race, gender and age. The patients were classified as moderate (<500), mild (150–500) or normal (<150) level of proteinuria in the urine. A 24 hour urine sample was obtained for analysis. Proteomic analysis was conducted by label free nLC MS/MS analysis.

Results The Principal Component Analysis (PCA) revealed differences between samples from patients who have high level of proteinuria in 24 hours and patients who do not have renal involvement. Interestingly, patients with mild proteinuria correlated better with patients without renal involvement than with the severe proteinuria group. A total of 292 proteins (identified with at least two peptides with a FDR<1%) were quantified and further considered in the analysis. Consistent with the nature of the sample, the Gene Ontology (GO analysis) of the whole list of identified proteins revealed the presence of extracellular (277 proteins, $p=2.25E-171$) and secretion-related proteins (49 proteins, $p=1.1E-09$), among others. Proteins related to defensive processes were prominent among them.

Interestingly, clear differences were detected between the three subgroups of samples. The Students T-test analysis reflected the differential presence of 147 proteins ($p<0.01$) between patients with and without renal involvement, being 17 more abundant in the urine of the patients with renal damage, whereas 130 showed the opposite pattern. The subset of proteins whose abundance increases upon renal damage is comprised of typical highly-abundant serum proteins. In addition, differences between most closely related groups (mild proteinuria and no renal affection) revealed differences that may be useful for a better stratification of patients.

Conclusions A different protein pattern is observed between the groups of patients, so in a more detailed study we may indicate if some of these can serve as prognostic markers for this type of patients.

Funding Source(s): No funding

Abstract 84 Table 1

Status	Accession	Un. Pepts	Score	Anova (p)	Ratio
Down upon damage	KLK1_HUMAN	2	105.38	2.37E-09	0.07
	CBPM_HUMAN	4	144.09	2.27E-08	0.10
	PVR_HUMAN	3	178.14	3.30E-08	0.15
	MASP2_HUMAN	3	213.26	5.71E-08	0.10
	KNG1_HUMAN	18	1100.55	7.86E-08	0.16
	BT2A1_HUMAN	2	96.76	1.88E-07	0.16
	I18BP_HUMAN	3	118.31	5.71E-07	0.08
	AMYP_HUMAN	2	650.58	6.01E-07	0.10
	AMY1_HUMAN	2	628.48	6.01E-07	0.10
	VMO1_HUMAN	4	342.57	6.68E-07	0.21
	VASN_HUMAN	6	498.27	9.25E-07	0.19
	APOD_HUMAN	7	403.15	1.06E-06	0.24
	CADM4_HUMAN	4	271.26	1.42E-06	0.21
	SHSA5_HUMAN	2	62.75	1.81E-06	0.15
	CNTFR_HUMAN	3	115.39	1.96E-06	0.05
UP upon damage	LRP2_HUMAN	13	798.35	2.19E-06	0.23
	CYTC_HUMAN	3	232.73	1.9E-03	1.42
	THBG_HUMAN	8	571.1	8.2E-03	2.47
	A2GL_HUMAN	10	801.87	3.3E-03	2.69
	CNDP1_HUMAN	2	150.97	8.1E-03	3.41
	CBG_HUMAN	7	492.53	4.2E-03	3.69
	HPT_HUMAN	18	1236.53	5.3E-03	3.76
	CFAB_HUMAN	2	155.83	2.0E-04	4.46
	TRFE_HUMAN	42	3539.5	7.5E-04	4.67
	ALBU_HUMAN	70	6073.45	2.3E-10	6.29
	A1AG2_HUMAN	8	834.2	1.3E-05	6.76
	A1AG1_HUMAN	10	996.35	1.3E-05	6.88
	AFAM_HUMAN	13	1120.44	1.2E-06	8.01
	A1AT_HUMAN	20	1493.01	3.6E-05	12.06
	CO3_HUMAN	9	693.16	6.8E-03	12.43
	A1BG_HUMAN	13	950.86	2.3E-04	15.19
	CFAD_HUMAN	4	224.79	9.7E-03	137.49

Representative deregulated proteins in case of renal damage. Adhesion: Uniprot Adhesion. United Nations. Pepts.: Unique peptides. Score: Score by mascot. Test T (p): p value for the T test used for the differential analysis. Relationship: Relationship between the abundances of proteins calculated in the samples of patients with renal involvement/samples without renal involvement.

85

POLYAUTOIMMUNITY IN SYSTEMIC LUPUS ERYTHEMATOSUS. DATA FROM A LARGE SPANISH COHORT: SPANISH SOCIETY OF RHEUMATOLOGY REGISTRY OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (RELESSER)

¹Natalia Mena-Vázquez*, ¹Antonio Fernandez Nebro, ²Iñigo Rúa-Figueroa, ³Maria Galindo Izquierdo, ⁴Juan Ovalles-Bonilla, ⁵Alejandro Olivé-Marqués, ⁶Jaime Calvo, ⁷Javier Narváez-García, ⁸Eva Tomero Muriel, ⁹Esther Uriarte Isacelayam, ¹⁰Alina Boteanu, ¹¹Mariano Andrés, ¹²Mercedes Freire González, ¹³Javier Narváez-García, ¹⁴Tomas R Vazquez Rodriguez, ¹⁵Ricardo Blanco, ¹⁶José A Hernández-Beriaín, ¹⁷Jesús Ibañez,

¹⁸Enrique Raya, ¹⁹Jose Maria Pego Reigosa. ¹UGC de Reumatología, Instituto de Investigación Biomédica de Málaga (IBIMA) Hospital Regional Universitario de Málaga, Spain; ²Department of Rheumatology, Dr Negrín General University Hospital, Las Palmas de Gran Canaria; ³Hospital Universitario 12 De Octubre; ⁴Hospital General Universitario Gregorio Marañón; ⁵Hospital German Trias i Pujol; ⁶Hospital Universitario Araba; ⁷Hospital de Bellvitge; ⁸Hospital De La Princesa; ⁹Hospital De Donostia; ¹⁰Hospital Ramón y Cajal; ¹¹Hospital General Universitario Alicante; ¹²Hospital Juan Canalejo A Coruña (CHUAC); ¹³Bellvitge University Hospital, Barcelona; ¹⁴Hospital Universitario Lucus Augusti; ¹⁵H. Marque de Valdecilla; ¹⁶Hospital Insular De Gran Canaria; ¹⁷Clinica Povisa; ¹⁸San Cecilio Hospital, Granada (Spain); ¹⁹Complejo hospitalario Universitario Vigo

10.1136/lupus-2019-lsm.85